Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AVNS vs CNMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CNMD Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–4 Matrix Metrics)

CNMD Overall Winner 6-Pillar Tally: AVNS 0 – 5 CNMD (1 Tie) Matrix Metrics: AVNS 4 – 6 CNMD

As of Nov 16, 2026, CONMED Corporation (CNMD) is the stronger overall head-to-head candidate over Avanos Medical, Inc. (AVNS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVNS carries a Unified Composite Score of 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin), whereas CNMD carries 37.0/100 (SELL) at $49.39 (10.7x Forward P/E, 10.2% operating margin).

  • Composite vs. Pillar Nuance: While AVNS currently prints a higher short-term Unified Composite Score (56.7/100 HOLD vs. CNMD 37.0/100 SELL), CNMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. 5.4% operating margin) and revenue trajectory (-0.7% vs. +8.8% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVNS vs CNMD
AVNS NYSE
Avanos Medical, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$24.99
+0.04% 1D
Market Cap $1.2B
TTM Revenue $716M
Forward P/E 20.0x
Beta / 30D Vol 1.22β · 6% Vol
Unified Composite Score
56.7 / 100 HOLD
Tech 75.0 Fund 59.0 Flow 50.0 Mom 46.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.0 · SMA20: $24.93 · SMA50: $24.90
CNMD NYSE Head-to-Head Winner
CONMED Corporation
Electromedical & Electrotherapeutic Apparatus
$49.39
-2.37% 1D
Market Cap $1.5B
TTM Revenue $1.37B
Forward P/E 10.7x
Beta / 30D Vol 0.87β · 61% Vol
Unified Composite Score
37.0 / 100 SELL
Tech 13.0 Fund 39.0 Flow 66.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 55.1 · SMA20: $49.05 · SMA50: $47.18

6-Pillar Scorecard Institutional Category Breakdown (AVNS 0 – 5 CNMD)

Columns: Metric · AVNS · CNMD
1. Valuation Multiples CNMD
Forward P/E 20.0x 10.7x
Trailing P/E 30.7x 20.9x
PEG Ratio N/M 1.84x
EV / Revenue 1.6x 1.7x
2. Growth & Scale CNMD
Revenue Growth (YoY) +8.8% -0.7%
Earnings Growth (YoY) -21.7% +633.3%
TTM Revenue (USD) $716M $1.37B
Market Cap $1.2B $1.5B
3. Profitability & Quality CNMD
Gross Margin 50.0% 54.8%
Operating Margin 5.4% 10.2%
Net Profit Margin -10.4% 5.4%
Return on Equity (ROE) -9.2% 7.1%
4. Balance Sheet & Cash Flow CNMD
Cash Generation (TTM) $56M EBITDA $133M
Cash Flow Margin 7.8% EBITDA Mgn 9.7%
Net Cash / Leverage $16.76 Book/Sh · -9.2% ROE $768M Net Debt (0.77x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CNMD
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 33.0% (50th %ile) 74.5% (8th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity 44.6% of Rev ($319M) 44.6% of Rev ($611M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVNS (4) vs CNMD (6)
Institutional Metric AVNS CNMD Criterion Row Edge
Market Capitalization
Scale
$1.2B $1.5B Larger Scale CNMD
Trailing P/E Ratio
Valuation
30.7x 20.9x Lower Multiple CNMD
Forward P/E Ratio
Valuation
20.0x 10.7x Lower Multiple CNMD
Revenue Growth (YoY)
Growth
+8.8% -0.7% Higher Growth AVNS
Operating Margin (TTM)
Profitability
5.4% 10.2% Higher Margin CNMD
Net Profit Margin
Profitability
-10.4% 5.4% Higher Margin CNMD
Return on Equity (ROE)
Capital Efficiency
-9.2% 7.1% Higher ROE CNMD
52-Week Range Position
Momentum
97% ($9–$25) 77% ($31–$55) Stronger Trend AVNS
Beta / 30D Volatility
Risk Regime
1.22β · 6% Vol 0.87β · 61% Vol Lower Realized Risk AVNS
Unified Institutional Score
Composite Signal
56.7 / 100 (HOLD) 37.0 / 100 (SELL) Higher Composite AVNS
Trailing 12M Revenue (USD)
Operating Scale
$716M $1.37B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
50.0% 54.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.6x EV/Rev 1.84x PEG · 1.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$56M EBITDA ($16.76 Book/Sh · -9.2% ROE) $133M ($768M Net Debt (0.77x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CNMD +20.4 pp
AVNS: +0.16% · CNMD: +20.56%
3M Horizon CNMD +12.68 pp
AVNS: +1.13% · CNMD: +13.81%
6M Horizon AVNS +89.53 pp
AVNS: +90.76% · CNMD: +1.23%
1Y Horizon AVNS +114.04 pp
AVNS: +112.68% · CNMD: -1.36%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVNS vs CNMD. Trailing 12-month operating profitability (AVNS 5.4% vs CNMD 10.2%) and valuation multiples (AVNS 20.0x vs CNMD 10.7x Forward P/E) are benchmarked directly in Pillar 4 below.

AVNS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$716M
Gross Margin50.0%
Op. Margin5.4%
ROE / Fwd P/E-9.2% · 20.0x
CNMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.37B
Gross Margin54.8%
Op. Margin10.2%
ROE / Fwd P/E7.1% · 10.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVNS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 33.0%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVNS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CNMD CONSOLIDATION
74d in phase · OBV DISTRIBUTION
Current IV 74.5%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CNMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVNS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.2B market capitalization and 5.4% operating margin.
OpEx & R&D Reinvestment 44.6% of Rev ($319M)
90D Engineering Disclosures 0 Published
CNMD Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.5B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 44.6% of Rev ($611M)
90D Engineering Disclosures 0 Published

Investor FAQ AVNS vs CNMD Key Questions & Quantitative Answers

As of Nov 16, 2026, CONMED Corporation (CNMD) is the stronger overall head-to-head candidate over Avanos Medical, Inc. (AVNS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVNS carries a Unified Composite Score of 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin), whereas CNMD carries 37.0/100 (SELL) at $49.39 (10.7x Forward P/E, 10.2% operating margin). Composite vs. Pillar Nuance: While AVNS currently prints a higher short-term Unified Composite Score (56.7/100 HOLD vs. CNMD 37.0/100 SELL), CNMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. 5.4% operating margin) and revenue trajectory (-0.7% vs. +8.8% YoY).

CNMD leads the Growth & Scale pillar: AVNS posts +8.8% YoY revenue growth and -21.7% YoY earnings growth on $716M TTM revenue (50.0% gross margin, 5.4% operating margin), compared with CNMD at -0.7% YoY revenue growth and +633.3% YoY earnings growth on $1.37B TTM revenue (54.8% gross margin, 10.2% operating margin). On trailing 12-month operating scale, AVNS generates $716M in USD-normalized revenue versus $1.37B for CNMD. In operating R&D and SG&A reinvestment, AVNS deploys 44.6% of Rev ($319M) (0 90-day corporate R&D disclosures) versus 44.6% of Rev ($611M) (0 disclosures) for CNMD.

CNMD screens cheaper on headline valuation multiples. AVNS trades at 20.0x Forward P/E, 30.7x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (7.8% EBITDA margin), whereas CNMD trades at 10.7x Forward P/E, 20.9x Trailing P/E, 1.84x PEG, and 1.7x EV/Revenue (9.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVNS (-9.2% ROE) versus CNMD (7.1% ROE) capital efficiency.

In options market volatility and institutional positioning, AVNS carries 33.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 6% Vol realized risk). By comparison, CNMD carries 74.5% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.87β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.